Help Privacy Policy Disclaimer
  Advanced SearchBrowse




Journal Article

Therapy of treatment resistant depression: Focus on the management of TRD with atypical antipsychotics

There are no MPG-Authors in the publication available
External Resource
No external resources are shared
Fulltext (restricted access)
There are currently no full texts shared for your IP range.
Fulltext (public)
There are no public fulltexts stored in PuRe
Supplementary Material (public)
There is no public supplementary material available

Klein, N., Sacher, J., Wallner, H., Tauscher, J., & Kasper, S. (2004). Therapy of treatment resistant depression: Focus on the management of TRD with atypical antipsychotics. CNS Spectrums, 9(11), 823-832. doi:10.1017/S1092852900002248.

Cite as: https://hdl.handle.net/21.11116/0000-0005-ACD5-9
Treatment-resistant depression (TRD) represents a significant challenge for physicians. About one third of patients with major depressive disorder fail to experience sufficient symptom improvement despite adequate treatment. Despite this high occurrence of TRD there was no general consensus on diagnosis criteria for TRD until 1997 when researchers proposed a model of defining and staging TRD. In 1999, others defined operational criteria for the definition of TRD. Treatment of TRD is commonly separated into pharmacologic and nonpharmacologic methods. This review gives a short overview of these two methods. The nonpharmacologic methods include psychotherapy, electroconvulsive therapy, and vagus nerve stimulation. Pharmacologic methods include switching to another antidepressant monotherapy, and augmentation or combination with two or more antidepressants or other agents. This review especially focuses on the augmentation of the antidepressant therapy with atypical antipsychotics.